Reports
Sale
Europe Chlorpheniramine Maleate Market Size, Share, Growth: By Dosage Form: Tablets, Syrup, Eye Drops, Others; By Application: Allergy, Hay Fever (Allergic Rhinitis), Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria; By Distribution Channel: Hospital Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Europe Chlorpheniramine Maleate Market Outlook
The global chlorpheniramine maleate market size was valued at USD 514.9 million in 2023, with Europe holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.
Key Takeaways
- Recent data revealed that one-third of the people living in the United Kingdom suffer from an allergy, with nearly 49% of Britons reported to suffer from seasonal hay fever. The rising prevalence of allergic conditions in the region is expected to drive market demand.
- One of the major Europe chlorpheniramine maleate market trends is the increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023, a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis.
- In the European Union, 21.3% of the population was estimated to be aged 65 years or older, according to Eurostat data published in January 2023. Since older adults are more likely to be affected by allergies, the market share for chlorpheniramine maleate products is expected to grow in the forecast period.
Europe Chlorpheniramine Maleate Market Analysis
Chlorpheniramine maleate is a widely popular antihistamine used to relieve symptoms like watery eyes, cough, runny nose, and rash from allergies, among others. The medication is usually taken orally and blocks histamine, a chemical released during an allergic reaction, to manage the associated symptoms. Given its antihistamine properties, over-the-counter chlorpheniramine maleate products are generally used to treat coughs and colds. Various clinical studies have also indicated its effectiveness in managing asthma, plasma cell gingivitis, and chronic urticaria. Thus, the rising clinical application of this antihistamine in treating various disease indications are significantly contributing to the Europe chlorpheniramine maleate market growth.
Allergic conditions are prevalent in Europe, affecting a substantial segment of the population. Recent data revealed that one-third of the people living in the United Kingdom suffer from an allergy, with nearly 49% of Britons reported to suffer from seasonal hay fever. Moreover, it is estimated that half of Europe’s population will be affected by allergies by 2025, which is expected to fuel the demand for allergy medications. Additionally, air pollution triggers allergic rhinitis and other respiratory allergies. For instance, aeroallergens can worsen asthma, which affects around 11% of the population in the United Kingdom . With the rising pollution levels and growing patient base suffering from allergies, the Europe chlorpheniramine maleate market share is poised to witness a surge in the coming years.
One of the major market trends is an increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023, a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis, a common respiratory illness. The study reported that the chlorpheniramine maleate-based throat spray resulted in significant improvement in symptoms within 3 days of use, reducing the overall time that the patient has symptoms. Such ongoing research initiatives that evaluate the efficacy of the antihistamine treatment in different disease indications are likely to augment the Europe chlorpheniramine maleate market value.
The incidence and severity of allergies tend to rise with age due to the development of chronic conditions and a decline in organ function. In the European Union, 21.3% of the population was estimated to be aged 65 years or older according to Eurostat data published in January 2023. Further, it was stated that the older population in the region is projected to increase significantly in the coming decades. With the rising number of older adults more likely to be affected by allergies, the market share for chlorpheniramine maleate products is expected to grow in the forecast period.
Europe Chlorpheniramine Maleate Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Dosage Form | Tablets, Syrup, Eye Drops, Others |
| Application | Allergy, Hay Fever (Allergic Rhinitis), Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
| Country | United Kingdom, Germany, France, Italy, Others |
Europe Chlorpheniramine Maleate Market: Competitor Landscape
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Viatris Inc.
- Bayer AG
- Merck KGaA
- Johnson & Johnson Medical Limited
- GSK plc
- AstraZeneca
- Sanofi
- Cardinal Health
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Dosage Form |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Chlorpheniramine Maleate Market Report Snapshots
Chlorpheniramine Maleate Market Size
Chlorpheniramine Maleate Market Analysis
Chlorpheniramine Maleate Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Chlorpheniramine Maleate Market Overview
3.1 Europe Chlorpheniramine Maleate Market Historical Value (2017-2023)
3.2 Europe Chlorpheniramine Maleate Market Forecast Value (2024-2032)
4 Europe Chlorpheniramine Maleate Market Landscape*
4.1 Europe Chlorpheniramine Maleate: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Chlorpheniramine Maleate: Product Landscape
4.2.1 Analysis by Dosage Form
4.2.2 Analysis by Application
5 Europe Chlorpheniramine Maleate Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Chlorpheniramine Maleate Market Segmentation (2017-2032)
6.1 Europe Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
6.1.1 Market Overview
6.1.2 Tablets
6.1.3 Syrup
6.1.4 Eye Drops
6.1.5 Others
6.2 Europe Chlorpheniramine Maleate Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Allergy
6.2.3 Hay Fever (Allergic Rhinitis)
6.2.4 Common Cold
6.2.5 Watery Eyes
6.2.6 Itchy Throat/Skin
6.2.7 Anaphylactic Shock
6.2.8 Urticaria
6.3 Europe Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.3.5 Others
6.4 Europe Chlorpheniramine Maleate Market (2017-2032) by Country
6.4.1 Market Overview
6.4.2 United Kingdom
6.4.3 Germany
6.4.4 France
6.4.5 Italy
6.4.6 Others
7 United Kingdom Chlorpheniramine Maleate Market (2017-2032)
7.1 United Kingdom Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
7.1.1 Market Overview
7.1.2 Tablets
7.1.3 Syrup
7.1.4 Eye Drops
7.1.5 Others
7.2 United Kingdom Chlorpheniramine Maleate Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Allergy
7.2.3 Hay Fever (Allergic Rhinitis)
7.2.4 Common Cold
7.2.5 Watery Eyes
7.2.6 Itchy Throat/Skin
7.2.7 Anaphylactic Shock
7.2.8 Urticaria
7.3 United Kingdom Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
7.3.1 Market Overview
7.3.2 Hospital Pharmacies
7.3.3 Retail Pharmacies
7.3.4 Online Pharmacies
7.3.5 Others
8 Germany Chlorpheniramine Maleate Market (2017-2032)
8.1 Germany Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
8.1.1 Market Overview
8.1.2 Tablets
8.1.3 Syrup
8.1.4 Eye Drops
8.1.5 Others
8.2 Germany Chlorpheniramine Maleate Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Allergy
8.2.3 Hay Fever (Allergic Rhinitis)
8.2.4 Common Cold
8.2.5 Watery Eyes
8.2.6 Itchy Throat/Skin
8.2.7 Anaphylactic Shock
8.2.8 Urticaria
8.3 Germany Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
8.3.1 Market Overview
8.3.2 Hospital Pharmacies
8.3.3 Retail Pharmacies
8.3.4 Online Pharmacies
8.3.5 Others
9 France Chlorpheniramine Maleate Market (2017-2032)
9.1 France Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
9.1.1 Market Overview
9.1.2 Tablets
9.1.3 Syrup
9.1.4 Eye Drops
9.1.5 Others
9.2 France Chlorpheniramine Maleate Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Allergy
9.2.3 Hay Fever (Allergic Rhinitis)
9.2.4 Common Cold
9.2.5 Watery Eyes
9.2.6 Itchy Throat/Skin
9.2.7 Anaphylactic Shock
9.2.8 Urticaria
9.3 France Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
9.3.1 Market Overview
9.3.2 Hospital Pharmacies
9.3.3 Retail Pharmacies
9.3.4 Online Pharmacies
9.3.5 Others
10 Italy Chlorpheniramine Maleate Market (2017-2032)
10.1 Italy Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
10.1.1 Market Overview
10.1.2 Tablets
10.1.3 Syrup
10.1.4 Eye Drops
10.1.5 Others
10.2 Italy Chlorpheniramine Maleate Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Allergy
10.2.3 Hay Fever (Allergic Rhinitis)
10.2.4 Common Cold
10.2.5 Watery Eyes
10.2.6 Itchy Throat/Skin
10.2.7 Anaphylactic Shock
10.2.8 Urticaria
10.3 Italy Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
10.3.1 Market Overview
10.3.2 Hospital Pharmacies
10.3.3 Retail Pharmacies
10.3.4 Online Pharmacies
10.3.5 Others
11 Others Regulatory Framework
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 Viatris Inc.
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Bayer AG
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Merck KGaA
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Johnson & Johnson Medical Limited
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 GSK plc
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 AstraZeneca
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Sanofi
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 Cardinal Health
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Novartis AG
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 Teva Pharmaceutical Industries Ltd.
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications
15 Europe Chlorpheniramine Maleate Market – Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Europe chlorpheniramine maleate market is expected to be driven by the rising demand for the global chlorpheniramine maleate market, which is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 848.1 million by 2032.
The growing prevalence of allergic conditions and the rising geriatric population in the region are fuelling the demand for the market.
One of the significant trends in the market is the increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023, a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis.
Based on the dosage form, the market is segmented into tablets, syrup, and eye drops, among others.
Distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Major applications of the chlorpheniramine maleate include allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.
The key players in the market are Viatris Inc., Bayer AG, Merck KGaA, Johnson & Johnson Medical Limited, GSK plc, AstraZeneca, Sanofi, Cardinal Health, Novartis AG, and Teva Pharmaceutical Industries Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER